Loss of the Nf1 Tumor Suppressor Gene Decreases Fas Antigen Expression in Myeloid Cells

American Journal of Pathology

Volumn 164, Issue 4, 2004, Pages 1471-1479

  Hiatt, Kelly ^a   Ingram, David A ^a   Huddleston, Hannah ^a   Spandau, Dan F ^a   Kapur, Reuben ^a   Clapp, D Wade ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P21; STEM CELL FACTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BONE MARROW CELL; CELL SURVIVAL; CONTROLLED STUDY; FIBROBLAST; GENE INACTIVATION; GENETIC ANALYSIS; HETEROZYGOSITY; IN VIVO STUDY; MAST CELL; MOUSE; MYELOID LEUKEMIA; NF1 GENE; NONHUMAN; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; STEM CELL; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 1642282700     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63233-6     Document Type: Article

References (47)

1. Coussens LM, Werb Z: Inflammation and cancer, Nature 2002, 420: 860-867
2. Coussens LM, Werb Z: Inflammatory cells and cancer: think different! J Exp Med 2001, 193:F23-F26
3. Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, New S, Hood A, Shannon K, Williams DA, Clapp DW: Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 2000, 191:181-188
4. Ingram DA, Hiatt K, King AJ, Fisher L, Shivakumar R, Derstine C, Wenning MJ, Diaz B, Travers JB, Hood A, Marshall M, Williams DA, Clapp DW: Hyperactivation of p21ras and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med 2001, 194: 57-70
5. Ryan JJ, Klein KA, Neuberger TJ, Leftwich JA, Westin EH, Kauma S, Fletcher JA, DeVries GH, Huff TF: Role for the stem cell factor/KIT complex in Schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis. J Neurosci Res 1994, 37:415-432
6. Hartmann K, Wagelie-Steffen AL, von Stebut E, Metcalfe DD: Fas (CD95, APO-1) antigen expression and function in murine mast cells. J Immunol 1997, 159;4006-4014
7. Wagelie-Steffen AL, Hartmann K, Vliagoftis H, Metcalfe DD: Fas ligand (FasL, CD95L, APO-1L) expression in murine mast cells. Immunology 1998, 94:569-574
8. Yeatman CF, 2nd, Jacobs-Helber SM, Mirmonsef P, Gillespie SR, Bouton LA, Collins HA, Sawyer ST, Shelburne CP, Ryan JJ: Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)-4 and IL-10 induces mouse mast cell apoptosis. J Exp Med 2000, 192: 1093-1103
9. Schneider E, Moreau G, Arnould A, Vasseur F, Khodabaccus N, Dy M, Ezine S: Increased fetal and extramedullary hematopoiesis in Fas-deficient C57BL/6-Ipr/Ipr mice. Blood 1999, 94:2613-2621
10. Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolff RK, Culver M, Carey JC, Copeland NG, Jenkins NA: Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990, 62:187-192
11. Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL: Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990, 249:181-186
12. +/--mast cells. J Clin Invest 2003, 112:1851-1861
13. Brodeur GM: The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. N Engl J Med 1994, 330:637-638
14. Side L, Taylor B, Cayouette M, Conner E, Thompson P, Luce M, Shannon K: Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997, 336:1713-1720
15. Neubauer A, Shannon KM, Liu E: Mutations of the ras proto-oncogenes in childhood monosomy 7. Blood 1991, 77:594-598
16. Shannon KM, Watterson J, Johnson P, O'Connell P, Lange B, Shah N, Steinherz P, Kan YW, Priest JR: Monosomy 7 myefoproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood 1992, 79:1311-1318
17. Shannon KM, O'Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F: Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994, 330:597-601
18. Emanuel PD, Bates LJ, Zhu SW, Castleberry RP, Gualtieri RJ, Zuckerman KS: The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. Exp Hematol 1991, 19:1017-1024
19. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG: Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 1996, 12:137-143
20. Bollag G, Clapp DW, Shih S, Adler F, Zhang Y, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K: Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in hematopoietic cells. Nat Genet 1996, 12:144-148
21. Zhang Y, Vik TA, Ryder JW, Srour EF, Jacks T, Shannon K, Clapp DW: Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med 1998, 187:1893-1902
22. Zhang Y, Taylor B, Shannon K, Clapp DW: Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. J Clin Invest 2001, 108:709-715
23. Ingram DA, Wenning MJ, Shannon K, Clapp DW: Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells. Blood 2003, 101: 1984-1986
24. Riccardi VM: Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. Baltimore, The John Hopkins University Press, 1992
25. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF: Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002, 296:920-922
26. Cichowski K, Jacks T: NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001, 104:593-604
27. McLaughlin ME, Jacks T: Thinking beyond the tumor cell: Nf1 haplo-insufficiency in the tumor environment. Cancer Cell 2002, 1:408-410
28. Hirota S, Nomura S, Asada H, Ito A, Morii E, Kitamura Y: Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch Pathol Lab Med 1993, 117:996-999
29. Tibbetts MD, Zheng L, Lenardo MJ: The death effector domain protein family: regulators of cellular homeostasis. Nat Immunol 2003, 4:404-409
30. Wajant H: The Fas signaling pathway: more than a paradigm. Science 2002, 296:1635-1636
31. Zhang B, Prendergast GC, Fenton RG: Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res 2002, 62:450-458
32. Peli J, Schroter M, Rudaz C, Hahne M, Meyer C, Reichmann E, Tschopp J: Oncogenic Ras inhibits Fas ligand-mediated apoptosis by down-regulating the expression of Fas. EMBO J 1999, 18:1824-1831
33. Kalas W, Kisielow P, Strzadala L: Inhibition of MEK induces fas expression and apoptosis in lymphomas overexpressing Ras. Leuk Lymphoma 2002, 43:1469-1474
34. Liu Q, Sasaki T, Kozieradzki I, Wakeham A, Itie A, Dumont DJ, Penninger M: SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev 1999, 13:786-791
35. Tan B, Yazicioglu MN, Ingram DA, McCarthy JB, Borneo J, Williams DA, Kapur R: Genetic evidence for convergence of c-Kit- and (α)4 integrin-mediated signals on class IA PI-3kinase and the Rac pathway in regulating integrin-directed migration in mast cells. Blood 2003, 101:4725-4732
36. Serve H, Yee NS, Stella G, Sepp-Lorenzino L, Tan JC, Besmer P: Differential roles of P13-kinase and kit tyrosine 821 in kit receptor-mediated proliferation, survival, and cell adhesion in mast cells. EMBO J 1995, 14:473-483
37. Hiatt K, Ingram DA, Zhang Y, Bollag G, Clapp DW; Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1 -/- cells. J Biol Chem 2001, 276:7240-7245
38. Haneline LS, Broxmeyer HE, Cooper S, Hangoc G, Carreau M, Buchwald M, Clapp DW: Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. Blood 1998, 91:4092-4098
39. Klose A, Ahmadian M, Schuelke M, Scheffzek K, Hoffmeyer S, Gewles A, Schmitz F, Kaufmann D, Peters H, Wittinghofer A, Nurnberg P: Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1 (NF1). Hum Mol Genet 1998, 7:1261-1268
40. Iemura A, Tsai M, Ando A, Wershil B, Galli S: The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol 1994, 144:321-328
41. Tsai M, Shih L-S, Newlands GFJ, Takeishi T, Langley K, Zsebo K, Miller H, Geissler EN, Galli S: C-kit ligand SCF, induces the development of connective tissue-type and mucosal mast cells in vivo: analysis by anatomical distribution, histochemistry, and protease phenotype. J Exp Med 1991, 174:125-131
42. Coussens LM, Raymond W, Bergers G, Webster M, Behrendtsen O, Z. W., Caughey G, Hanahan D: Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999, 13:1382-1397
43. Bollag G, McCormick F: NF is enough of GAP. Nature 1992, 356:663-664
44. Alenzi FQ, Marley SB, Lewis JL, Chandrashekran A, Warrens AN, Goldman JM, Gordon MY: A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics. Exp Hematol 2002, 30:1428-1435
45. Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS: Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997, 90: 4266-4270
46. Beltinger C, Kurz E, Bohler T, Schrappe M, Ludwig WD, Debatin KM: CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 1998, 91:3943-3951
47. Tamiya S, Etoh K, Suzushima H, Takatsuki K, Matsuoka M: Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood 1998, 91:3935-3942